Reading problems of the bottom third: grades one through six

Thesis (Ed.M.)--Boston Universit

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination

Trial design: In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3–5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination. Methods: Circulating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5 th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3–5 years of age for a subgroup of study children. Results: Serotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers 0.35µg/ml and 1.0 µg/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3–5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3–5 years of age between the three groups. Conclusions: Immunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness. © 2017 van den Biggelaar et al

REVIEW: SOLUTIONS FOR GRAND CHALLENGES IN GOAT AND SHEEP PRODUCTION INDUSTRY

Goats and sheep are valuable as they are a source of meat, milk, fleece, and other products. These livestock are also important both for agriculture and biomedical research. However, the efficient, sustainable, and profitable production of these small ruminants faces major obstacles. Hence, this review analyzes these major challenges specifically, their negative impacts on the industry, and suggests some science-based solutions to overcome them. Those challenged areas are education and training, research, translational research/biotechnology, goat and sheep health, and maintenance of an economically sustainable agribusiness. The suggested solutions include the effective teaching of goat and sheep science to the next generation and public empowerment, support for innovative and translational research, disease prevention and treatment, support for technology transfer, and development of sound agribusiness practices. This review is helpful particularly for scientists, students, and the goat and sheep producers. In general, these information on the current state of goat and sheep agriculture will also help the public to better understand and appreciate the challenges met and opportunities provided in small ruminant production enterprises